Advertisement
Canada markets open in 6 hours 52 minutes

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7259
    -0.0005 (-0.07%)
     

  • CRUDE OIL

    83.88
    +1.15 (+1.39%)
     

  • Bitcoin CAD

    86,179.16
    +2,001.73 (+2.38%)
     

  • CMC Crypto 200

    1,280.75
    -31.87 (-2.43%)
     

  • GOLD FUTURES

    2,396.70
    -1.30 (-0.05%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     

  • NASDAQ futures

    17,402.25
    -145.00 (-0.83%)
     

  • VOLATILITY

    18.00
    -0.21 (-1.15%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6820
    -0.0001 (-0.01%)
     

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023

Business Wire
·2 min read

SAN DIEGO, April 26, 2023--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2023 after the market close on Tuesday, May 9 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 9, 2023.

Arcturus Therapeutics First Quarter 2023 Earnings Conference Call

  • Tuesday, May 9, 2023 @ 4:30 p.m. ET

  • Domestic: 1-888-886-7786

  • International: 1-416-764-8658

  • Conference ID: 70942720

  • Webcast: Link

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005037/en/

Contacts

IR and Media Contacts
Arcturus Therapeutics
Neda Safarzadeh
VP, Head of IR/PR/Marketing
(858) 900-2682
IR@arcturusrx.com

Kendall Investor Relations
Carlo Tanzi, Ph.D.
(617) 914-0008
ctanzi@kendallir.com